Inclusion Criteria:

- Patient has a confirmed diagnosis of a solid tumor or hematological malignancy with
the exception of endometrial cancer, glioblastoma, nonsmall cell lung cancer,
prostate cancer or breast cancer.

- Patient's tumor has been evaluated and pre-identified to have activation of the PI3K
pathway, at a CLIA certified laboratory

- Patient must have received at least one prior treatment for metastatic and /or
locally advanced disease and for whom no standard therapy options are anticipated to
result in a durable remission.

- Patient must have measurable disease as per RECIST v1.1. or other appropriate
hematological guidelines

- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Exclusion Criteria:

Patient has received previous treatment with BKM120 Patient has symptomatic CNS metastases
Patient has mood disorder as outlined in Section 5 Patient has received chemotherapy or
targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C)
prior to starting study drug.